A Heartbreaking Dual Battle: Parents Fight Rare Blood Cancer in Christchurch

For the King family in Christchurch, life has taken a devastating turn. Maureen and Jeff King, both parents to Alexander and Brydie, are currently battling the same rare and aggressive blood cancer — multiple myeloma — a condition that has no known cure. Their story is one of resilience, love, and the heartbreaking reality of facing a terminal illness.

Maureen, 70, was diagnosed with multiple myeloma eight years ago and has since relied on medication to manage the disease. But as her current treatment is losing its effectiveness, she has opted for an experimental and costly treatment in China — a decision that has been made even more difficult by Jeff’s recent diagnosis.

Jeff, 73, was diagnosed with multiple myeloma just weeks before Maureen’s planned trip to China for experimental CAR-T cell therapy. His prognosis is dire, and he is expected to meet with a specialist soon to learn his estimated life expectancy. The news has left the family reeling, with Alexander describing the situation as “a cruel twist of fate.”

The impact on the family has been profound. Alexander, who had recently quit his job as a barber, has traveled to China to accompany his mother during her treatment, while his sister Brydie has remained in Christchurch to care for their father. Both have described the emotional toll as overwhelming, with Brydie even requiring hospitalization due to stress-related health issues.

Despite the heartbreak, the family has tried to make the most of their time together. They have shared meals, gone bowling, and spent quality time at each other’s homes, creating lasting memories in the face of uncertainty.

The treatment Maureen is undergoing in Kunming is both experimental and risky. It involves extracting T cells from her body, genetically engineering them, and returning them to fight cancer. While the success rate is estimated at 70%, the potential side effects are severe, including stroke, brain damage, and the possibility of death. The family has already discussed the possibility of losing Maureen and has prepared for the worst.

Meanwhile, Jeff’s treatment options are limited. The drug daratumumab, which could extend his life, is not currently funded by Pharmac, the Crown entity responsible for public funding of medicines. This has left the family grappling with the financial burden, though they have received some support through donations and a Givealittle fundraising campaign.

Pharmac has explained that its decision not to fund daratumumab is based on a limited budget and a careful assessment of cost, efficacy, and health system benefits. While the organization has not ruled out future funding, the current situation has left patients like Jeff in a difficult position.

As the family continues to face this dual battle, their story is a stark reminder of the challenges faced by those dealing with rare and aggressive cancers. It also highlights the importance of advocacy, the role of public funding, and the strength of a family united in love and support.